Literature DB >> 35035724

Effects of radical cystectomy combined with GC chemotherapy in the treatment of invasive bladder cancer and its influence on the incidence of adverse reactions.

Dewen Ban1, Wei Lu1, Zheng Lu1, Bin Li1, Naichun Zhou1.   

Abstract

OBJECTIVE: To explore the efficiency of radical cystectomy combined with GC chemotherapy in the treatment of invasive bladder cancer and its influence on the incidence of adverse reactions.
METHODS: The clinical data of 120 patients with invasive bladder cancer admitted to our hospital from February 2015 to February 2016 were retrospectively analyzed. According to different treatment methods, they were equally divided into two groups. The experimental group (n=60) was treated with radical cystectomy combined with GC chemotherapy. The control group (n=60) was treated with bladder-preserving comprehensive treatment (transurethral bladder tumor resection + internal iliac artery infusion chemotherapy + intravesical infusion chemotherapy). The short-term efficiency, adverse reactions, long-term treatment indicators, survival, surgical indicators, and quality of life were compared between the two groups.
RESULTS: The two groups showed similar objective remission rate and disease control rate (P>0.05). Both groups of patients had different degrees of hematological toxicity and non-hematological toxicity, but no severe systemic organ toxicity. Fewer patients in the experimental group experienced anemia and fever compared with the control group (P<0.05). The incidence of recurrence, hydronephrosis, and metastasis in the experimental group was significantly lower than that in the control group (P<0.05). The experimental group showed a higher 3-year survival rate than the control group (86.7% vs 75.0%), with no statistical difference between the two groups (P>0.05). The experimental group obtained a significantly higher 5-year survival rate than that of the control group (70.0% vs 51.7%) (P<0.05). The experimental group outperformed the control group in terms of surgical indicators (P<0.001). The two groups had similar quality of life scores after the 5-year follow-up (P>0.05).
CONCLUSION: Radical cystectomy combined with GC for the treatment of invasive bladder cancer reduces the incidence of adverse reactions and enhances the 5-year survival of patients, with a promising long-term efficiency. AJTR
Copyright © 2021.

Entities:  

Keywords:  GC chemotherapy; Radical cystectomy; invasive bladder cancer

Year:  2021        PMID: 35035724      PMCID: PMC8748082     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  23 in total

Review 1.  Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives.

Authors:  Georgios Gakis
Journal:  Eur Urol Focus       Date:  2020-01-25

Review 2.  The role of laparoscopic and robotic cystectomy in the management of muscle-invasive bladder cancer with special emphasis on cancer control and complications.

Authors:  Ben J Challacombe; Bernard H Bochner; Prokar Dasgupta; Inderbir Gill; Khurshid Guru; Harry Herr; Alexander Mottrie; Raj Pruthi; Joan Palou Redorta; Peter Wiklund
Journal:  Eur Urol       Date:  2011-05-17       Impact factor: 20.096

3.  Correction to: SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).

Authors:  M Lázaro; E Gallardo; M Doménech; Á Pinto; A González-Del-Alba; J Puente; O Fernández; A Font; N Lainez; S Vázquez
Journal:  Clin Transl Oncol       Date:  2019-06       Impact factor: 3.405

Review 4.  SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Authors:  Jeffrey J Leow; Jens Bedke; Karim Chamie; Justin W Collins; Siamak Daneshmand; Petros Grivas; Axel Heidenreich; Edward M Messing; Trevor J Royce; Alexander I Sankin; Mark P Schoenberg; William U Shipley; Arnauld Villers; Jason A Efstathiou; Joaquim Bellmunt; Arnulf Stenzl
Journal:  World J Urol       Date:  2019-01-25       Impact factor: 4.226

Review 5.  Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage.

Authors:  Christian Daniel Fankhauser; Jeremy Yuen-Chun Teoh; Hugh Mostafid
Journal:  Curr Opin Urol       Date:  2020-05       Impact factor: 2.309

6.  Reasons for intravesical instillation postponement during adjuvant treatment of non-muscle-invasive bladder cancer: A prospective study.

Authors:  W Khan; A S Zugail; E Blanc; Y Neuziller; T Lebret
Journal:  Prog Urol       Date:  2020-01-14       Impact factor: 0.915

7.  Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy.

Authors:  Marieke J Krimphove; Julie Szymaniak; Maya Marchese; Karl H Tully; David D'Andrea; Matthew Mossanen; Stuart R Lipsitz; Kerry Kilbridge; Adam S Kibel; Luis A Kluth; Shahrokh F Shariat; Quoc-Dien Trinh
Journal:  Eur Urol Focus       Date:  2019-06-18

8.  Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy.

Authors:  Benjamin W Fischer-Valuck; Jeff M Michalski; Joanna G Harton; Alison Birtle; John P Christodouleas; Jason A Efstathiou; Vivek K Arora; Eric H Kim; Eric M Knoche; Russell K Pachynski; Joel Picus; Yuan James Rao; Melissa Reimers; Bruce J Roth; Paul Sargos; Zachary L Smith; Mohamed S Zaghloul; Hiram A Gay; Sagar A Patel; Brian C Baumann
Journal:  Clin Genitourin Cancer       Date:  2020-06-22       Impact factor: 2.872

9.  Relationship of frailty with treatment modality selection in patients with muscle-invasive bladder cancer (FRART-BC study).

Authors:  Hiromichi Iwamura; Shingo Hatakeyama; Masaki Momota; Yuta Kojima; Takuma Narita; Teppei Okamoto; Naoki Fujita; Itsuto Hamano; Kyou Togashi; Tomoko Hamaya; Tohru Yoneyama; Hayato Yamamoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  Transl Androl Urol       Date:  2021-03

Review 10.  Current and innovative approaches in the treatment of non-muscle invasive bladder cancer: the role of transurethral resection of bladder tumor and organoids.

Authors:  Milena Taskovska; Mateja Erdani Kreft; Tomaz Smrkolj
Journal:  Radiol Oncol       Date:  2020-05-02       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.